National Center for Tumor Diseases, Germany
Dr. Nicolas Hohmann is currently heading the Early Clinical Trials Group at the National Center for Tumor Diseases in Heidelberg, Germany. He is a clinical pharmacologist by training. He earned his MD from the University Hospital Mainz, Germany, and then completed residency and fellowship at the University Hospital of Heidelberg. He is currently completing training in medical oncology. He is currently studying the role of cytochrom p450 isozymes in the non-response or failure of anticancer therapy. He has published both original research and review articles on this topic. He has been a member of ASCPT since 2013.